Yuko Hidaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuko Hidaka has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Hana Inoue
Department of Physiology, Tokyo Medical University, Tokyo, Japan
1 shared publication - Kazufumi Nakamura
Department of Cardiovascular Medicine, Shimane University Faculty of Medicine, Izumo, Japan
1 shared publication - Keiko Uchida
Department of Physiology (M.K., Y.K., S.I., K.U., H.I., Y.H., U.Y.), Tokyo Medical University, Japan
1 shared publication - Mariko Ono
Department of Physiology (M.K., Y.K., S.I., K.U., H.I., Y.H., U.Y.), Tokyo Medical University, Japan
1 shared publication Mayumi Yokotsuka
Department of Anatomic Pathology (M.Y., Y.Y., T.N.), Tokyo Medical University, Japan
1 shared publication- Roger R. Reddel
ProCan®, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (9)
Mechanosensitive Stanniocalcin-1 Suppresses Smooth Muscle Cell Proliferation and Attenuates Experimental Pulmonary Hypertension
BACKGROUND: Idiopathic pulmonary arterial hypertension (IPAH) is driven by progressive vascular remodeling, particularly smooth muscle cell (SMC) proliferation. Current combination vasodilator therapies have markedly improved outcomes; however, prognosis remains poor in subgroups such as patients with respiratory comorbidities. Elevation of intravascular hydrostatic pressure is a hallmark of IPAH, yet its direct role in pulmonary artery SMCs remains unclear. We aimed to identify pressure-responsive mediators using a newly developed hydrostatic pressurization system to model hypertensive hemodynamics. METHODS: Pulmonary artery SMCs from 4 patients with IPAH were exposed to high hydrostatic pressure (70/40 mm Hg, 60 bpm). Transcriptomic profiling identified differentially expressed genes, which were validated by quantitative polymerase chain reaction. Functional studies included PIEZO1 (piezo type mechanosensitive ion channel component 1) modulation, rhSTC1 (recombinant human stanniocalcin-1) treatment, bromodeoxyuridine incorporation, and Western blotting for cell-cycle regulators. Chronic hypoxia–induced pulmonary hypertension was assessed in wild-type and Stc1 –/– mice by hemodynamic and histological analyses, with or without intratracheal rhSTC1 administration. RESULTS: RNA sequencing revealed STC1 to be a pressure-induced gene in IPAH SMCs. PIEZO1 activation upregulated STC1 , whereas knockdown blunted this response. STC1 was upregulated in IPAH lungs, while rhSTC1 reduced pulmonary arterial SMC proliferation and increased p-p53, p21, and p27 expression. Stc1 –/– mice under hypoxia exhibited significantly higher right ventricular systolic pressure and greater pulmonary arterial medial thickness than wild-type mice. CD68-positive macrophages were increased in Stc1 –/– mice under normoxia and further elevated with hypoxia. Intratracheal administration of rhSTC1 attenuated PAH in wild-type and Stc1 –/– mice. CONCLUSIONS: Elevated hydrostatic pressure drives STC1 expression via PIEZO1, suggesting an adaptive but insufficient protective response in IPAH. Modulation of STC1 (stanniocalcin-1) may represent a potential therapeutic approach.
- 9 October 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (9)
Open AccessMechanosensitive Stanniocalcin-1 Suppresses Smooth Muscle Cell Proliferation and Attenuates Experimental Pulmonary Hypertension
BACKGROUND: Idiopathic pulmonary arterial hypertension (IPAH) is driven by progressive vascular remodeling, particularly smooth muscle cell (SMC) proliferation. Current combination vasodilator therapies have markedly improved outcomes; however, prognosis remains poor in subgroups such as patients with respiratory comorbidities. Elevation of intravascular hydrostatic pressure is a hallmark of IPAH, yet its direct role in pulmonary artery SMCs remains unclear. We aimed to identify pressure-responsive mediators using a newly developed hydrostatic pressurization system to model hypertensive hemodynamics. METHODS: Pulmonary artery SMCs from 4 patients with IPAH were exposed to high hydrostatic pressure (70/40 mm Hg, 60 bpm). Transcriptomic profiling identified differentially expressed genes, which were validated by quantitative polymerase chain reaction. Functional studies included PIEZO1 (piezo type mechanosensitive ion channel component 1) modulation, rhSTC1 (recombinant human stanniocalcin-1) treatment, bromodeoxyuridine incorporation, and Western blotting for cell-cycle regulators. Chronic hypoxia–induced pulmonary hypertension was assessed in wild-type and Stc1 –/– mice by hemodynamic and histological analyses, with or without intratracheal rhSTC1 administration. RESULTS: RNA sequencing revealed STC1 to be a pressure-induced gene in IPAH SMCs. PIEZO1 activation upregulated STC1 , whereas knockdown blunted this response. STC1 was upregulated in IPAH lungs, while rhSTC1 reduced pulmonary arterial SMC proliferation and increased p-p53, p21, and p27 expression. Stc1 –/– mice under hypoxia exhibited significantly higher right ventricular systolic pressure and greater pulmonary arterial medial thickness than wild-type mice. CD68-positive macrophages were increased in Stc1 –/– mice under normoxia and further elevated with hypoxia. Intratracheal administration of rhSTC1 attenuated PAH in wild-type and Stc1 –/– mice. CONCLUSIONS: Elevated hydrostatic pressure drives STC1 expression via PIEZO1, suggesting an adaptive but insufficient protective response in IPAH. Modulation of STC1 (stanniocalcin-1) may represent a potential therapeutic approach.